clinical trial · NCT00649129
Fasting Study of Oxybutynin Chloride ER Tablets 10 mg and Ditropan XL® Tablets 10 mg
HealthyOxybutynin Chloride ER Tablets 10 mgDitropan XL® Tablets 10 mg
brief summary
The objective of this study was to investigate the single-dose relative bioavailability of Mylan's oxybutynin chloride extended-release tablets to ALZA's Ditropan XL® tablets following an oral, single 20 mg (2 x 10 mg) dose under fasting conditions.
started
Jul 1, 2002
primary completion
Aug 1, 2002
completion
Aug 1, 2002
last updated
Apr 24, 2024
official title
Single-Dose Fasting In Vivo Bioequivalence Study of Oxybutynin Chloride ER Tablets (10 mg; Mylan) and Ditropan XL® Tablets (10 mg; ALZA) in Healthy Volunteers
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol